CLINICAL TRIAL TO EVALUATE EFFICACY AND SAFETY OF OCTAGAM 10% IN PATIENTS WITH DERMATOMYOSITIS (ProDERM Study)

• Register: EUCTR
• Last refreshed on: 26 March 2024
• Main ID: EUCTR2016-002902-37-CZ
• Date of registration: 26/09/2016
• Prospective Registration: Yes
• Primary sponsor: Octapharma Pharmazeutika Produktionsges.m.b.H.
• Public title: CLINICAL TRIAL TO EVALUATE EFFICACY AND SAFETY OF OCTAGAM 10% IN PATIENTS WITH DERMATOMYOSITIS (ProDERM Study)
• Scientific title: PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF OCTAGAM 10% IN PATIENTS WITH DERMATOMYOSITIS - (ProDERM Study)
• Date of first enrolment: 20/12/2016
• Target sample size: 94
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002902-37
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: no Cross over: no Other: yes Other trial design description: double blind trial with an open label extension period If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 2
• Phase: Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no

Countries of recruitment

Canada, Czech Republic, France, Germany, Hungary, Netherlands, Poland, Romania, Russian Federation, Ukraine, United States

Contacts

• Name: Global Clinical Project Manager
• Affiliation: Octapharma Pharmazeutika Produktionsges.m.b.H.

• Name: Global Clinical Project Manager
• Affiliation: Octapharma Pharmazeutika Produktionsges.m.b.H.

Key inclusion & exclusion criteria

Inclusion criteria:
1.Subjects with diagnosis of definite or probable DM according to the Bohan and Peter criteria.
2.Subjects under treatment with corticosteroids and/or maximally 2 immune-suppressants and being on stable therapy for at least 4 weeks (see Section 4.2.1) OR Subjects with previous failure of response or previous intolerance to corticosteroid and at least 1 additional immunosuppressive drug, and with steroid/immunosuppressive drugs ashed out as per Section 4.2.1 (Table 2).
3. Subjects with active disease, assessed and agreed upon by an independent adjudication committee. being on stable therapy for at least
4 weeks.
4. Manual Muscle Testing-8 (MMT-8) score <142, with at least 2 other abnormal Core Set Measures (CSM) (Visual Analogue Scale [VAS] of patient global activity =2 cm, physician's global disease activity =2 cm, extra-muscular activity =2 cm; at least one muscle enzyme >1.5 times upper limit of normal, Health Assessment Questionnaire =0.25).
5. Males or females = 18 to < 80 years of age.
6. Voluntarily given, fully informed written consent obtained from subject before any study-related procedures are conducted.
7. Subject must be capable to understand and comply with the relevant aspects of the study protocol.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 84
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10

Exclusion criteria:
1. Cancer-associated myositis, defined as the diagnosis of myositis
within 2 years of the diagnosis of cancer (except basal or squamous cell
skin cancer or carcinoma in situ of the cervix that has been excised and
cured and at least 1 or 5 years, respectively have passed since excision).
2. Evidence of active malignant disease or malignancies diagnosed
within the previous 5 years (including hematological malignancies and
solid tumors) or breast cancer diagnosed within the previous 10 years.
3. Subjects with overlap myositis (except for overlap with Sjögren's
syndrome), connective tissue disease associated DM, inclusion body
myositis, polymyositis, juvenile dermatomyositis or drug-induced
myopathy.
4. Subjects with immune-mediated necrotizing myopathy with absence
of typical DM rash.
5. Subjects with generalized, severe musculoskeletal conditions other
than DM that prevent a sufficient assessment of the subject by the
physician.
6. Subjects who have received IgG treatment within the last 6 months
before enrolment.
7. Subjects who received blood or plasma-derived products (other than
IgG) or plasma exchange within the last 3 months before enrolment.
8. Subjects starting or planning to start a physical therapy–directed
exercise regimen during the trial.
9. Cardiac insufficiency (New York Heart Association III/IV),
cardiomyopathy, significant cardiac dysrhythmia requiring treatment,
unstable or advanced ischemic heart disease.
10. Severe liver disease, with signs of ascites and hepatic
encephalopathy.
11. Severe kidney disease (as defined by estimated glomerular filtration
rate (eGFR) < 30 mL/min/1.73 m2).
12. Known hepatitis B, hepatitis C or HIV infection.
13. Subjects with a history of TEE such as deep vein thrombosis,
pulmonary embolism, myocardial infarction, ischemic stroke, transient
ischemic attack, peripheral artery disease (Fontaine IV) ever.
14. Body mass index =40 kg/m2.
15. Medical conditions whose symptoms and effects could alter protein
catabolism and/or IgG utilization (e.g. protein-losing enteropathies,
nephrotic syndrome).
16. Known IgA deficiency with antibodies to IgA.
17. History of hypersensitivity, anaphylaxis or severe systemic response
to immuno-globulin, blood or plasma derived products or any component
of Octagam 10%.
18. Known blood hyperviscosity, or other hypercoagulable states.
19. Subjects with a history of drug abuse within the past 5 years prior to
study enrollment.
20. Subjects unable or unwilling to understand or comply with the study
protocol.
21. Participating in another interventional clinical study with
investigational treatment within 3 months prior to study enrollment.
22.Women who are breast feeding, pregnant, or planning to become
pregnant, or are unwilling to apply an effective birth control method
(such as implants, injectables, combined oral contraceptives, some
intrauterine devices [IUDs], sexual abstinence or vasectomized partner)
up to four weeks after the last IMP infusion.
23.Subjects who are accommodated in an institution or care facility
based on an official directive or court order.
24.Subjects who are in any way dependent on the Sponsor, Investigator
or Study Site.
25.Subjects who received forbidden medication within the washout
period as defined in Section 4.2.2 (Table 3).


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Therapeutic area: Body processes [G] - Immune system processes [G12]

Dermatomyositis
MedDRA version: 20.0 Level: LLT Classification code 10001403 Term: Adult dermatomyositis System Organ Class: 100000004858

Intervention(s)

Trade Name: Octagam 10%
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: IMMUNOGLOBULIN G
CAS Number: 308067-58-5
Concentration unit: % percent
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous drip use (Noncurrent)

Primary Outcome(s)

Primary end point(s): Proportion of responders in the 2.0 g/kg Octagam 10% and placebo arms at Week 16. A responder is defined as a subject with an increase from baseline (Week 0) of =20 points on the Total Improvement Score (TIS).

Main Objective: To provide confirmatory data on the beneficial effect of 2.0 g/kg of Octagam 10% given every 4 weeks compared with placebo in subjects with active DM based on the percentage of responders at Week 16.

Secondary Objective: To evaluate the beneficial effect of Octagam 10% in subjects with active DM by assessing different parameters and scores at Week 16 and Week 40;
To confirm the sustained benefit of treatment with Octagam 10% by assessing the primary response measures at Week 40;
To evaluate the safety and tolerability of Octagam 10% in subjects with DM.

Timepoint(s) of evaluation of this end point: Week 16

Secondary Outcome(s)

Timepoint(s) of evaluation of this end point: Week 16 and 40

Secondary end point(s): -Proportion of TIS responders by improvement category (minimal, moderate, major) at Week 16 and Week 40.
-Mean change from baseline (Week 0) to end of First Period (Week 16) in the modified Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI).
- Mean change from end of First Period (Week 16) to end of Extension Period (Week 40) in the modified CDASI.
-Mean change from Baseline (Week 0) to end of First Period (Week 16) and Extension Period (Week 40) in:
- SF-36v2 Health Survey;
- Individual 6 CSM used for TIS calculation.
- Mean change in TIS from Baseline (Week 0) to end of First Period (Week 16) and from Baseline (Week 0) to end of Extension Period (Week 40).
- Time to minimal, moderate and major improvement in TIS.
- Time to confirmed deterioration in the First Period and overall.

Secondary ID(s)

GAM10-08

NCT02728752

16925

Source(s) of Monetary Support

Octapharma Pharmazeutika Produktionsges.m.b.H.

Ethics review

Status: Approved
Approval date: 05/10/2016
Contact:

Results

• Results available: Yes
• Date Posted: 20/11/2020
• Date Completed: 05/11/2019
• URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002902-37/results